Drug Information

Drug (ID: DG01245) and It's Reported Resistant Information

• Name: Canagliflozin
• Synonyms: Canagliflozin; 842133-18-0; Invokana; Canagliflozin anhydrous; TA-7284; JNJ-28431754; JNJ 24831754ZAE; canagliflozin hemihydrate; UNII-6S49DGR869; Canagliflozin hydrate; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; TA 7284; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; CHEBI:73274; 6S49DGR869; (2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; (1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol; D-Glucitol,1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-, (1S)-; JNJ 28431754; (1S)-1,5-Anhydro-1-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-D-glucitol; (1s)-1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-d-glucitol; JNJ 24831754AAA; (2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol; Canagliflozin [INN]; JNJ 24831754; MLS006011126; SCHEMBL157162; C24H25FO5S; GTPL4582; CHEMBL2048484; HSDB 8284; AMY3291; BCPP000303; DTXSID601004469; JNJ 28431754AAA; BDBM50386885; MFCD18251436; s2760; ZINC43207238; AKOS025401827; BCP9000477; CCG-229581; CS-0522; DB08907; KS-1443; NCGC00346691-02; (1S)-1,5-Anhydro-1-c-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-D-glucitol; AC-26303; HY-10451; SMR004702906; SW219119-1; Y0287; A25050; J-500391; Q5030940; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methyl-phenyl)-D-glucitol; 1,5-Anhydro-1-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)hexitol; D-Glucitol, 1,5-anhydro-1-C-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4- methylphenyl)-, (1S)-; D-glucitol, 1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4- methylphenyl)-, (1s)-; JNJ24831754ZAE; TA 7284;(2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol
• Indication:
  In total 4 Indication(s)
  Diabetic nephropathy [ICD-11: GB61]; Approved; [1]
  Type-1 diabetes [ICD-11: 5A10]; Approved; [1]
  Type-2 diabetes [ICD-11: 5A11]; Approved; [1]
  Type-2 diabetes [ICD-11: 5A11]; Approved; [1]
• Target: Sodium/glucose cotransporter 2 (SGLT2); SC5A2_HUMAN; [1]
• Formula: C24H25FO5S
• IsoSMILES: CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F
• InChI: 1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
• InChIKey: XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
• PubChem CID: 24812758
• ChEBI ID: CHEBI:73274
• TTD Drug ID: D08DFX
• VARIDT ID: DR00279
• INTEDE ID: DR0262
• DrugBank ID: DB08907

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-05: Endocrine/nutritional/metabolic diseases

Type 2 diabetes mellitus [ICD-11: 5A11]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Solute carrier family 5 member 2 (SLC5A2) [1]

• Molecule Alteration: Function; Inhibition
• Sensitive Disease: Type 2 diabetes mellitus [ICD-11: 5A11.0]
• Experimental Note: Identified from the Human Clinical Data
• Mechanism Description: Treatment with the SGLT2 (sodium-glucose cotransporter 2) inhibitor canagliflozin results in early and sustained reductions in systolic blood pressure in people with type 2 diabetes and chronic kidney disease, regardless of baseline blood pressure, number of blood pressure lowering agents, and history of apparent treatment-resistant hypertension.

ICD-16: Genitourinary system diseases

Chronic kidney disease [ICD-11: GB61]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Solute carrier family 5 member 2 (SLC5A2) [1]

• Molecule Alteration: Function; Inhibition
• Sensitive Disease: Chronic kidney disease [ICD-11: GB61.0]
• Experimental Note: Identified from the Human Clinical Data
• Mechanism Description: Treatment with the SGLT2 (sodium-glucose cotransporter 2) inhibitor canagliflozin results in early and sustained reductions in systolic blood pressure in people with type 2 diabetes and chronic kidney disease, regardless of baseline blood pressure, number of blood pressure lowering agents, and history of apparent treatment-resistant hypertension.

References

• Ref 1: Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial .Circulation. 2021 May 4;143(18):1735-1749. doi: 10.1161/CIRCULATIONAHA.120.048740. Epub 2021 Feb 8. 10.1161/CIRCULATIONAHA.120.048740